{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:46:11Z","timestamp":1782974771344,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the efficacy of Duloxetine and Nortriptyline in alleviating the symptoms of severity, anxiety, depression and quality of life in patients with functional dyspepsia (FD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and method<\/jats:title><jats:p>We conducted a single-blinded 3-month trial of Duloxetine 20\u201330\u2009mg daily in 20 patients and Nortriptyline 25\u2009mg daily in 25 FD patients. The primary outcome measure was the severity of FD symptoms by Gastrointestinal symptoms rating scale. Secondary measures included Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, and Nepean Dyspepsia Index. the patients were measured in 3 stages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>45 patients with FD with a mean age of 37.18\u2009\u00b1\u200910.62\u2009years participated in the study. The severity of symptoms was significantly lower in the Nortriptyline group than in the Duloxetine group after three months (<jats:italic>p<\/jats:italic> =\u20090.031). The level of anxiety (<jats:italic>p<\/jats:italic> =\u20090.049), depression (<jats:italic>p<\/jats:italic> =\u20090.045) and quality of life (<jats:italic>p<\/jats:italic> =\u20090.046) improved significantly after three months in the Duloxetine group compared to Nortriptyline. Mediation analysis using linear regression revealed a significant mediator role for anxiety. This mediation analysis revealed a 21.13% reduction in anxiety in the Duloxetine group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While both medications demonstrated efficacy, Nortriptyline appeared to be superior in symptom reduction. Duloxetine exhibited more advantages compared to Nortriptyline in addressing anxiety and depression and enhancing the overall quality of life. Also, Duloxetine may have a noteworthy impact, contributing to a 20% reduction in FD symptoms by lowering anxiety levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/en.irct.ir\/trial\/65512<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1297231","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:39:07Z","timestamp":1705379947000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparing the efficacy of duloxetine and nortriptyline in alleviating the symptoms of functional dyspepsia \u2013 a randomized clinical trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Seyed Shahab","family":"Banihashem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Mahsa","family":"Mofatioshieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhaneh","family":"Rastegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0140-6736(20)30469-4","article-title":"Functional dyspepsia","volume":"396","author":"Ford","year":"2020","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2014-307843","article-title":"Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis","volume":"64","author":"Ford","year":"2015","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/gutjnl-2022-327737","article-title":"British Society of Gastroenterology guidelines on the management of functional dyspepsia","volume":"71","author":"Black","year":"2022","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/2040622317725479","article-title":"Management of functional dyspepsia: state of the art and emerging therapies","volume":"9","author":"Yamawaki","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1365-2982.2012.01985.x","article-title":"Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal?","volume":"24","author":"Clauwaert","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5056\/jnm14096","article-title":"Brain-based correlations between psychological factors and functional dyspepsia","volume":"21","author":"Nan","year":"2015","journal-title":"J Neurogastroenterol Motil"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrgastro.2013.10","article-title":"The role of psychosocial factors and psychiatric disorders in functional dyspepsia","volume":"10","author":"Van Oudenhove","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2036.2010.04510.x","article-title":"Risk factors for impaired health-related quality of life in functional dyspepsia","volume":"33","author":"Van Oudenhove","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e14396","DOI":"10.1111\/nmo.14396","article-title":"Cine gastricMRIreveals alteredGut\u2013BrainAxis in functional dyspepsia: gastric motility is linked with brainstem\u2010corticalfMRIconnectivity","volume":"34","author":"Sclocco","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMra1501505","article-title":"Functional dyspepsia","volume":"373","author":"Talley","year":"2015","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1126\/science.abi6087","article-title":"Signaling inflammation across the gut-brain axis","volume":"374","author":"Agirman","year":"2021","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-med-042320-014032","article-title":"The gut\u2013brain axis","volume":"73","author":"Mayer","year":"2022","journal-title":"Annu Rev Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e26046","DOI":"10.1097\/MD.0000000000026046","article-title":"Comparative efficacy and acceptability of psychotropic drugs for functional dyspepsia in adults: a systematic review and network meta-analysis","volume":"100","author":"Zhou","year":"2021","journal-title":"Medicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/gutjnl-2015-310721","article-title":"Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis","volume":"66","author":"Ford","year":"2017","journal-title":"Gut"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut\u2212 brain interaction): a Rome foundation working team report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11894-018-0664-3","article-title":"Psychotropics, antidepressants, and visceral analgesics in functional gastrointestinal disorders","volume":"20","author":"T\u00f6rnblom","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1008841022998","article-title":"Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease","volume":"7","author":"Revicki","year":"1997","journal-title":"Qual Life Res"},{"key":"ref18","first-page":"18","article-title":"Comparison between psychometric characteristics of Persian version of the gastrointestinal symptoms rating scale in functional gastrointestinal disorders and normal groups","volume":"17","author":"Mazaheri","year":"2012","journal-title":"Govaresh"},{"key":"ref19","first-page":"10","article-title":"Hamilton anxiety scale","volume":"1","author":"Hamilton","year":"1959","journal-title":"Group"},{"key":"ref20","first-page":"56","article-title":"The Hamilton depression scale\u2014accelerator or break on antidepressant drug discovery","volume":"23","author":"Hamilton","year":"1960","journal-title":"Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2010.12.007","article-title":"Reliability of the Hamilton rating scale for depression: a meta-analysis over a period of 49 years","volume":"189","author":"Trajkovi\u0107","year":"2011","journal-title":"Psychiatry Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/NDT.S103869","article-title":"Validity and test\u2013retest reliability of the Persian version of the Montgomery\u2013asberg depression rating scale","volume":"12","author":"Ahmadpanah","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2036.1999.00445.x","article-title":"Development of a new dyspepsia impact scale: the Nepean dyspepsia index","volume":"13","author":"Talley","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2036.2012.05128.x","article-title":"Current treatment options and management of functional dyspepsia","volume":"36","author":"Lacy","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-022-06492-6","article-title":"Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (the ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care","volume":"23","author":"Alderson","year":"2022","journal-title":"Trials"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2169\/internalmedicine.52.9147","article-title":"A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome","volume":"52","author":"Chao","year":"2013","journal-title":"Intern Med"},{"key":"ref27","volume-title":"O51 amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (the ATLANTIS study): a double-blind placebo-controlled trial","author":"Ford","year":"2023"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4103\/cmi.cmi_13_21","article-title":"Amitriptyline in irritable bowel syndrome: a clinical review","volume":"19","author":"Rajagopalan","year":"2021","journal-title":"Curr Med Issues"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.22037\/ghfbb.v16i1.2513","article-title":"Comparison of the potency of nortriptyline and mirtazapine on gastrointestinal symptoms, the level of anxiety and depression in patients with functional dyspepsia","volume":"16","author":"Jamshidfar","year":"2023","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jgh.13914","article-title":"Efficacy and safety of nortriptyline in functional dyspepsia in Asians: a randomized double-blind placebo-controlled trial","volume":"33","author":"Kaosombatwattana","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1365-2982.2007.01029.x","article-title":"The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial","volume":"20","author":"Choung","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/JCP.0000000000000599","article-title":"An open-label pilot study of duloxetine in patients with irritable bowel syndrome and comorbid major depressive disorder","volume":"36","author":"Lewis-Fern\u00e1ndez","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/hup.1038","article-title":"Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study","volume":"24","author":"Brennan","year":"2009","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1023\/A:1018878324327","article-title":"Tricyclic antidepressants for functional nausea and vomiting (clinical outcome in 37 patients)","volume":"43","author":"Prakash","year":"1998","journal-title":"Dig Dis Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.15191","article-title":"Treatment options for functional dyspepsia","volume":"49","author":"Masuy","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref36","first-page":"678","article-title":"Treatment of functional GI disorders with psychotropic medicines: a review of evidence with a practical approach","volume":"2","author":"Thiwan","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"ref37","volume-title":"Essential psychopharmacology: Neuroscientific basis and practical applications","author":"Stahl","year":"2000"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/bs.apha.2015.11.002","article-title":"The pharmacology of visceral pain","volume":"75","author":"Johnson","year":"2016","journal-title":"Adv Pharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1297231\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T04:39:14Z","timestamp":1705379954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1297231\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":38,"alternative-id":["10.3389\/fpsyt.2023.1297231"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1297231","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"article-number":"1297231"}}